Jean‐Yves Blay

2.4k total papers · 94.3k total citations
1.2k papers, 44.9k citations indexed

About

Jean‐Yves Blay is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Gastroenterology. According to data from OpenAlex, Jean‐Yves Blay has authored 1.2k papers receiving a total of 44.9k indexed citations (citations by other indexed papers that have themselves been cited), including 767 papers in Pulmonary and Respiratory Medicine, 462 papers in Oncology and 279 papers in Gastroenterology. Recurrent topics in Jean‐Yves Blay's work include Sarcoma Diagnosis and Treatment (575 papers), Gastrointestinal Tumor Research and Treatment (279 papers) and Vascular Tumors and Angiosarcomas (165 papers). Jean‐Yves Blay is often cited by papers focused on Sarcoma Diagnosis and Treatment (575 papers), Gastrointestinal Tumor Research and Treatment (279 papers) and Vascular Tumors and Angiosarcomas (165 papers). Jean‐Yves Blay collaborates with scholars based in France, United States and United Kingdom. Jean‐Yves Blay's co-authors include Axel Le Cesne, Paolo G. Casali, Jaap Verweij, Isabelle Ray‐Coquard, Axel Le Cesne, Ian Judson, M. van Glabbeke, Peter Reichardt, Christine Ménétrier‐Caux and Antoîne Italiano and has published in prestigious journals such as Proceedings of the National Academy of Sciences, The Lancet and Journal of Clinical Investigation.

In The Last Decade

Jean‐Yves Blay

1.1k papers receiving 44.0k citations

Hit Papers

Progression-free survival... 2004 2026 2011 2018 2004 2014 2006 2009 2009 400 800 1.2k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation benchmark for papers published in the same subfield and year, or reaches the top citation threshold in at least one of its specific research topics.

  1. Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial
    2004 1.3k citations Jaap Verweij, Paolo G. Casali et al. The Lancet profile →
  2. Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trial
    2014 809 citations Ian Judson, Jaap Verweij et al. The Lancet Oncology profile →
  3. KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumours
    2006 655 citations Maria Dêbiec‐Rychter, Raf Sciot et al. European Journal of Cancer profile →
  4. Lymphopenia as a Prognostic Factor for Overall Survival in Advanced Carcinomas, Sarcomas, and Lymphomas
    2009 617 citations Isabelle Ray‐Coquard, Claire Cropet et al. Cancer Research profile →
  5. Regulatory T Cells Recruited through CCL22/CCR4 Are Selectively Activated in Lymphoid Infiltrates Surrounding Primary Breast Tumors and Lead to an Adverse Clinical Outcome
    2009 560 citations Michael Gobert, Isabelle Treilleux et al. Cancer Research profile →
  6. Eribulin versus dacarbazine in previously treated patients with advanced liposarcoma or leiomyosarcoma: a randomised, open-label, multicentre, phase 3 trial
    2016 537 citations Patrick Schöffski, Sant P. Chawla et al. The Lancet profile →
  7. Pazopanib, a Multikinase Angiogenesis Inhibitor, in Patients With Relapsed or Refractory Advanced Soft Tissue Sarcoma: A Phase II Study From the European Organisation for Research and Treatment of Cancer–Soft Tissue and Bone Sarcoma Group (EORTC Study 62043)
    2009 534 citations Stefan Sleijfer, Isabelle Ray‐Coquard et al. Journal of Clinical Oncology profile →
  8. Denosumab in patients with giant-cell tumour of bone: an open-label, phase 2 study
    2010 512 citations David M. Thomas, Robert M. Henshaw et al. The Lancet Oncology profile →
  9. Neo-adjuvant chemotherapy alone or with regional hyperthermia for localised high-risk soft-tissue sarcoma: a randomised phase 3 multicentre study
    2010 483 citations Rolf D. Issels, Lars H. Lindner et al. The Lancet Oncology profile →
  10. Effect of the MDM2 antagonist RG7112 on the P53 pathway in patients with MDM2-amplified, well-differentiated or dedifferentiated liposarcoma: an exploratory proof-of-mechanism study
    2012 453 citations Isabelle Ray‐Coquard, Jean‐Yves Blay et al. The Lancet Oncology profile →
  11. Safety and efficacy of denosumab for adults and skeletally mature adolescents with giant cell tumour of bone: interim analysis of an open-label, parallel-group, phase 2 study
    2013 425 citations Sant P. Chawla, Robert M. Henshaw et al. The Lancet Oncology profile →
  12. Efficacy and Safety of Trabectedin in Patients With Advanced or Metastatic Liposarcoma or Leiomyosarcoma After Failure of Prior Anthracyclines and Ifosfamide: Results of a Randomized Phase II Study of Two Different Schedules
    2009 397 citations George D. Demetri, Sant P. Chawla et al. Journal of Clinical Oncology profile →
  13. Gastrointestinal stromal tumours: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
    2010 382 citations Paolo G. Casali, Jean‐Yves Blay Annals of Oncology profile →
  14. Incidence of Sarcoma Histotypes and Molecular Subtypes in a Prospective Epidemiological Study with Central Pathology Review and Molecular Testing
    2011 380 citations Françoise Ducimetière, A. Lurkin et al. PLoS ONE profile →
  15. Denosumab Induces Tumor Reduction and Bone Formation in Patients with Giant-Cell Tumor of Bone
    2012 330 citations Jean‐Yves Blay, Sant P. Chawla et al. Clinical Cancer Research profile →
  16. Deep learning-based classification of mesothelioma improves prediction of patient outcome
    2019 311 citations Pierre Courtiol, Charles Maussion et al. Nature Medicine profile →
  17. The standard diagnosis, treatment, and follow-up of gastrointestinal stromal tumors based on guidelines
    2015 310 citations Toshirou Nishida, Jean‐Yves Blay et al. profile →
  18. Ripretinib in patients with advanced gastrointestinal stromal tumours (INVICTUS): a double-blind, randomised, placebo-controlled, phase 3 trial
    2020 246 citations Jean‐Yves Blay, César Serrano et al. The Lancet Oncology profile →
  19. Efficacy and safety of regorafenib in adult patients with metastatic osteosarcoma: a non-comparative, randomised, double-blind, placebo-controlled, phase 2 study
    2018 224 citations Florence Duffaud, Olivier Mir et al. The Lancet Oncology profile →
  20. Gastrointestinal stromal tumours
    2021 213 citations Jean‐Yves Blay, Yoon‐Koo Kang et al. profile →
  21. Endoscopic management of subepithelial lesions including neuroendocrine neoplasms: European Society of Gastrointestinal Endoscopy (ESGE) Guideline
    2022 169 citations Jean‐Yves Blay et al. profile →

Author Peers

Peers are selected by citation overlap in the author's most active subfields. citations · hero ref

Author Last Decade Papers Cites
Jean‐Yves Blay 26.3k 19.3k 8.8k 7.0k 6.9k 1.2k 44.9k
George D. Demetri 23.6k 0.9× 11.1k 0.6× 16.9k 1.9× 3.5k 0.5× 8.9k 1.3× 346 37.9k
Christopher D.�M. Fletcher 41.2k 1.6× 20.1k 1.0× 14.4k 1.6× 13.0k 1.9× 15.0k 2.2× 674 69.7k
Robert G. Maki 18.2k 0.7× 9.7k 0.5× 7.9k 0.9× 3.2k 0.5× 5.3k 0.8× 377 26.1k
Murray F. Brennan 43.2k 1.6× 38.6k 2.0× 10.5k 1.2× 6.8k 1.0× 31.6k 4.6× 954 80.9k
Ian Judson 16.4k 0.6× 10.8k 0.6× 6.4k 0.7× 3.4k 0.5× 5.0k 0.7× 402 27.9k
Robert S. Benjamin 14.1k 0.5× 11.8k 0.6× 3.3k 0.4× 2.9k 0.4× 4.2k 0.6× 493 25.8k
Paolo G. Casali 18.7k 0.7× 8.3k 0.4× 6.5k 0.7× 3.1k 0.5× 5.4k 0.8× 430 24.5k
M. van Glabbeke 17.9k 0.7× 15.5k 0.8× 4.7k 0.5× 4.3k 0.6× 9.3k 1.3× 197 35.3k
Pancras C.W. Hogendoorn 15.2k 0.6× 6.9k 0.4× 2.4k 0.3× 2.5k 0.4× 3.6k 0.5× 441 26.0k
Ronald P. DeMatteo 19.2k 0.7× 19.3k 1.0× 9.8k 1.1× 1.9k 0.3× 23.5k 3.4× 540 46.2k

Countries citing papers authored by Jean‐Yves Blay

Since Specialization
Citations

This map shows the geographic impact of Jean‐Yves Blay's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jean‐Yves Blay with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jean‐Yves Blay more than expected).

Fields of papers citing papers by Jean‐Yves Blay

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jean‐Yves Blay. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jean‐Yves Blay. The network helps show where Jean‐Yves Blay may publish in the future.

Co-authorship network of co-authors of Jean‐Yves Blay

This figure shows the co-authorship network connecting the top 25 collaborators of Jean‐Yves Blay. A scholar is included among the top collaborators of Jean‐Yves Blay based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jean‐Yves Blay. Jean‐Yves Blay is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Loading papers...

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Hideyuki Okano Breakdown of academic impact, for papers by Reinhard Dummer Breakdown of academic impact, for papers by Shengzhong Liu Breakdown of academic impact, for papers by Lars Køber Breakdown of academic impact, for papers by Michael B. Hursthouse Breakdown of academic impact, for papers by Razelle Kurzrock Breakdown of academic impact, for papers by Kenneth H. Mayer Breakdown of academic impact, for papers by Yuichiro� Doki
Rankless by CCL
2026